HWA
AVEO

HCR Wealth Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

HCR Wealth Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,472
Closed -$28K – 192
2019
Q1 		$28K Buy
+3,472
New +$35.8K 0.01% 169

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

HCR Wealth Advisors's AVEO Position: Q2 2019 in Review

HCR Wealth Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2019, closing a stake of 3,472 shares — an estimated $28K sold.

HCR Wealth Advisors first reported a position in AVEO in Q1 2019 and held it in 1 quarter. The position peaked at $28K in Q1 2019. 73 funds tracked by Wall St. Rank hold AVEO as of Q2 2019.

  • HCR Wealth Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • HCR Wealth Advisors sold 3,472 AVEO Pharmaceuticals, Inc. shares in Q2 2019, an estimated $28K.
  • HCR Wealth Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • HCR Wealth Advisors's AVEO Pharmaceuticals, Inc. position peaked at $28K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2019.

Based on HCR Wealth Advisors's 13F filing for Q2 2019, filed 25 Jul 2019.